CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma

NCT00374179 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: CT-322

Sponsor

Adnexus, A Bristol-Myers Squibb R&D Company